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Abstract 
Japanese encephalitis is frequent in Asia, with a severe prognosis, but rare in travelers. Culex mosquitoes 
transmit Japanese encephalitis virus. Risk factors are destination, duration of stay, summer and fall seasons, 
outdoors activities and type of accommodation. We report the case of a French traveler to Nepal with 
neutralization-based serological confirmed Japanese Encephalitis. He presented classical clinical (viral syndrome 
before an encephalitis status with behavioral disorder, global hypotonia, mutism, movement disorders, seizure 
and coma), radiological (lesions of thalami, cortico-spinal tracts and brainstem) and biological features 
(lymphocytic meningitis). Nowadays, the presence of Japanese Encephalitis Virus in Nepal, including mountain 
areas is established but Japanese Encephalitis remains rare in travelers returning from this area and neurologist 
physicians need to become familiar with this. We recommend vaccination for travelers spending a long period of 
time in Nepal and having at-risk outdoor activities.  
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Introduction 
Japanese encephalitis (JE) is an arboviral disease due to the eponymous Flavivirus (JEV) transmitted by Culex 
mosquitoes. JEV is prevalent throughout Eastern, Southern Asia and Pacific Ring Area (Misra et al, 2010). JE is 
one of the most frequent causes of encephalitis in the world with about 67,000 cases (incidence: 1.8/100.000) 
leading to 15,000 deaths annually (Campbell et al, 2011). JE leads to a severe prognosis: mortality approaches 
30% of symptomatic cases and 50% of survivors present severe sequelae (Oya et al, 2007).  
The risk of infection by JEV is low for travelers visiting Asia: less than one case per one million travelers (Hatz 
et al, 2009). This risk depends on the duration of stay, the season of travel, the practice of outdoor 
accommodations/activities, and the itinerary (Hills et al, 2010). No specific treatment exists, but a vaccine is 
available. We report a case of JE in a French traveler returning from travel in Nepal. 
Case description 
Our case concerns a 22-year-old man who stayed in Nepal as a volunteer for a non-governmental organization 
from May to September 2012. His past medical history included heavy smoking and HIV seropositivity (without 
immunodepression [533 CD4/mm3] and no antiretroviral therapy). Seven days after trekking in Pokhara area he 
presented a viral syndrome (headache, hyperthermia, asthenia) quickly followed by an agitated delirium (Day 9), 
then multiple seizures (Day 11) leading to coma. Routine biological tests were normal. The CD4 lymphocyte 
count was 892/mm
3
. Cerebral tomodensitometry (CT) showed diffuse edema. Magnetic Resonance Imaging 
(MRI) revealed brainstem and di-encephalic lesions (thalami, cortico-spinal tracts, and corpus callosum on T2 & 
FLAIR sequences) without any evidence of either bleeding (T2 EG) or enhancement after gadolinium injection 
(fig. 2a). Cerebro-Spinal Fluid (CSF) analysis showed lymphocytic meningitis (452 cells/mm
3
), slightly elevated 
protein rate (56 mg/dl) and normal glucose rate.  Extensive plasma analyses (including serology for Hepatitis A-
E viruses,  Epstein-Barr virus, Rubella, Dengue virus, Measles, Chikungunya, Treponema, Rickettsia species, 
Tularemia, Bartonella, Ehrlichia, Mycoplasma, Legionella, Thick blood smear) and CSF analyses (direct exam, 
bacteriological, parasitological cultures and viral PCR [HSV, VZV, Measles, Toxoplasmosis, JC virus, HHV-6, 
Toscana virus, Mumps virus, Lymphocytic Choriomeningitis virus, Adenovirus, Listeria, Cryptococcus, 
Leptospirosis, Tropheryma whipplei, Borrelia] ) were negative or not conclusive. Unfortunately neither plasma 
nor CSF pan-flavivirus PCR was available during the acute stage of the disease. After his repatriation into 
France, the definitive diagnosis was established by demonstrating that the serum contained neutralizing 
antibodies at a titre of 2,500 using the classic neutralization methods with JEV, West Nile virus, the four dengue 
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viruses, and Yellow fever virus. An innovative fluorescent bead-based multiplex serological assay using the 
Luminex  xMAP method and associating up to 20 types of recombinant domain III (rEDIII) from flavivirus 
(Vanhomwegen and Desprès, unpublished data) confirmed the results. 
Multiple antibiotics regimens (Amoxicillin, Amikacin 500mg daily, Ceftriaxone 2g daily, Meropenem, 
Itraconazole 100mg daily, Zithromax 500 mg daily, Acyclovir 750 mg daily, Rifampicine 600 mg daily, 
Isoniazide 300 mg daily, Pyrazinamide 500 mg daily, Ethambutol 1g daily) and Corticosteroid (1 mg/kg/day) 
had remained inefficient despite 3 weeks of treatment. The patient was repatriated from Nepal to Bangkok one 
week after the onset and back to France two months after the onset. He was hospitalized in our neurology 
department with poor clinical condition: drowsiness, mutism, quadriparesia, axial hypotonia (seated position was 
impossible), paroxysmal axial dystonia, and severe swallowing disorders (needing a gastrostomy). He presented 
multiple episodes of partial complex seizures. 
Progressively he improved, and after 2 months of reeducation he was able to walk, to swallow and talk normally. 
He was free of seizure but he conserved a mild distal motor deficit of right upper limb and a total amnesia of the 
episode. Six months after the onset the patient was showing important behavioral disorders (impulsivity, 
intolerance to frustration, difficulties in social relationship); and one year later only mild impulsivity, moderate 
attention disorders and memory recall deficiency persisted. In accordance with this evolution, the MRI showed 
dramatic regression of lesions (Fig 1) 
Discussion 
JEV is transmitted between infected vertebrates through the bite of mosquitoes (mainly Culex 
tritaeniorhynchus); pigs and aquatic birds play pivotal roles as amplifying hosts. Therefore, incidence rates are 
much higher in rural areas, where pigs, aquatic birds and paddy-breeding vector mosquitoes are prevalent. Direct 
diagnosis of JE is seldom made since early clinical manifestations lack specificity. We report a case with a 
diagnosis of JE laboratory-confirmed by demonstration of the presence of neutralizing antibodies specific to JEV 
in a previously non-exposed French traveler. Our case presents classical characteristics of JE (displayed in 
Figure 2 and Table 1). The clinical features include an incubation period (5-15 days) followed by an aspecific 
viral syndrome (headache, fever), then an encephalitis syndrome (seizure, motor and sensorium deficit, 
movement disorders, Parkinsonism, behavioral troubles, coma). Seizures are often multiple, mostly generalized 
tonico-clonic and possibly leading to status epilepticus. Motor deficits are quadriplegia more than hemiplegia, 
upper limbs more than lower limbs, and can be due to lower or upper motor neuron lesion. Movement disorders 
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include tremor, chorea, focal dystonia, myoclonus and oro-facial dyskinesia. (Misra et al, 2010; Basumatary et 
al, 2012). Radiological explorations, based on MRI, are abnormal in 80% of cases with T2-hypersignal and T1 
iso/hyposignal (topographies are resumed in Table 1). Bilateral thalami lesions are highly evocative. (Kalita et 
al, 2000). CSF analyses are abnormal in more than 80% of cases. The clinical course consists of an acute short-
lived illness and a prolonged convalescence.  
Imported cases of JE remain rare but their incidence has been increasing for the last three decades (Hills et al, 
2010; Buhl and Lindquist 2009). Whereas JE mostly concerns the pediatric population in endemics areas, 
residents of all ages of developed countries have no immunity to JEV and are susceptible to severe infection. 
However, short-term tourism has not been associated with a significant risk for contracting JE. The Katmandu 
Valley is now well-known for endemic transmission of JEV (Thakkur et al, 2012; Impoinvil et al, 2011; 
Bhattachan et al, 2009; Partridge et al, 2007). For travelers to rural areas where JE is endemic, the estimated risk 
for JE during the transmission period is 1 per 20,000 per week (Halstead & Tsai 2004). Because of the 
availability of a vaccine, the nature of the stay of this patient was in adequation with immunization 
recommendations (long stay, endemic geographic area, HIV+, outdoor professional and leisure activities, travel 
itinerary including rural areas) (Burchard et al 2009). 
Conclusion 
This case of JE in a French traveler returning from Nepal reemphasizes the need to disseminate revised 
recommendations on travel vaccines towards general practitioners and the general population. In the context of 
the recent increase in incidence of imported JE cases (Buhl and Lindquist 2009, Tappe et al 2012, Werlinrud et 
al 2011), it is crucial for neurologists to be aware of the possibility of JE in their at-risk population. They also 
must become familiar with the epidemiological, clinical and paraclinical features consistent with the diagnosis of 
JE. 
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Figure 1: T2 sequences of cerebral MRI 15 days (A) and 5 month (B) after the onset. 
 
A 
B 
A: lesion of thalami, brainstem and cortico-spinal tracts 
B: dramatic regression of lesion after 5 month 
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Figure 2: JE Clinical Features 
 
 
 
 
Table 1: JE CSF Analysis, MRI and EEG Features 
CSF Analysis 
(Median value) 
MRI Lesions 
(Prevalence) 
EEG 
 Mild Protein rates elevation (70mg/dl) 
 Pleiocytosis (66,5/mm3) 
 Lymphocytic predominance 
 Thalami (94%) 
 Midbrain (58 %) 
 Basal ganglia (38,5%) 
 Cerebellum (25.8% 
 Pons (19%) 
 Cortex (19%) 
 Diffuse background activity slowing 
 Spike-Wave discharges 
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